Loading...
XWAR
NNG
Market cap20mUSD
Jul 09, Last price  
2.44PLN
1D
-4.31%
1Q
-1.61%
IPO
-42.59%
Name

Nanogroup SA

Chart & Performance

D1W1MN
XWAR:NNG chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
14.40%
Rev. gr., 5y
-64.09%
Revenues
0k
-100.00%
7,4037,403040,798110,289351,832687,507492,491139,5492,0192,1000
Net income
-9m
L+82.77%
-716,176-716,176000-1,537,652-5,189,259-10,005,432-838,592-7,889,820-5,167,663-9,445,071
CFO
-9m
L+53.88%
-126,107-126,107000-1,576,9610-3,199,113-3,684,912-4,761,015-5,716,320-8,796,135

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

NanoGroup S.A. operates as a biotechnology company in Poland. It engages in the production of medicines and other pharmaceutical products, and research and development work in the field of biotechnology and other natural and technical sciences. The company is also involved in technical research and analysis. In addition, it manages a portfolio of companies that manage projects to meet the needs of modern medicine in the field of oncology and transplantology. The company was founded in 2016 and is based in Warsaw, Poland.
IPO date
Dec 21, 2017
Employees
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT